Publication:
Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain

Thumbnail Image

Files

EstimatedImpactNirsevimabVRS_2024.pdf (1.82 MB)
Supplement_EstimatedImpactNirsevimabVRS_2024.pdf (984.56 KB)
Identifiers
URI: http://hdl.handle.net/20.500.12105/19872
DOI: 10.1111/irv.13294

Publication date

2024-05

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publishers

Metrics
Google Scholar
Export
MarcXML METS

Research Projects

Organizational Units

Journal Issue

Abstract

Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards. Methods: Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23. Results: We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction.

Description

Keywords

SARI Burden Impact Respiratory infections Respiratory syncitial virus Surveillance

MeSH Terms

Respiratory Syncytial Virus Infections Hospitalization Antiviral Agents Humans Spain Infant Incidence Female Male Respiratory Syncytial Virus, Human Sentinel Surveillance Infant, Newborn Antibodies, Monoclonal, Humanized

DeCS Terms

Bibliographic citation

Influenza Other Respir Viruses. 2024 May;18(5):e13294.

Collections

Centro Nacional de Epidemiología (CNE)
IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)

Publisher version

https://doi.org/10.1111/irv.13294

Related dataset

Related publication

Document type

research article